Homeodomain proteins, described 30 years ago 1, 2 , exert essential roles in development as regulators of target gene expression 3, 4 ; however, the molecular mechanisms underlying transcriptional activity of homeodomain factors remain poorly understood. Here investigation of a developmentally required POU-homeodomain transcription factor, Pit1 (also known as Pou1f1), has revealed that, unexpectedly, binding of Pit1-occupied enhancers 5 to a nuclear matrin-3rich network/architecture 6, 7 is a key event in effective activation of the Pit1-regulated enhancer/coding gene transcriptional program. Pit1 association with Satb1 (ref. 8 ) and b-catenin is required for this tethering event. A naturally occurring, dominant negative, point mutation in human PIT1(R271W), causing combined pituitary hormone deficiency 9 , results in loss of Pit1 association with b-catenin and Satb1 and therefore the matrin-3-rich network, blocking Pit1dependent enhancer/coding target gene activation. This defective activation can be rescued by artificial tethering of the mutant R271W Pit1 protein to the matrin-3 network, bypassing the pre-requisite association with b-catenin and Satb1 otherwise required. The matrin-3 network-tethered R271W Pit1 mutant, but not the untethered protein, restores Pit1-dependent activation of the enhancers and recruitment of co-activators, exemplified by p300, causing both enhancer RNA transcription and target gene activation. These studies have thus revealed an unanticipated homeodomain factor/b-catenin/ Satb1-dependent localization of target gene regulatory enhancer regions to a subnuclear architectural structure that serves as an underlying mechanism by which an enhancer-bound homeodomain factor effectively activates developmental gene transcriptional programs.
During pituitary development, the POU-homeodomain transcription factor, Pit1, is necessary for differentiation of thyrotrope, lactotrope and somatotrope cell types in both mice and humans 10, 11 . To further understand the molecular basis for Pit1-mediated gene activation, we mapped the genomic localization of Pit1 by chromatin immunoprecipitation followed by sequencing (ChIP-seq) using antibody specific against Pit1 (Extended Data Fig. 1a, b ) in a growth hormone (GH)expressing rat pituitary cell line (GC). Of 14, 466 Pit1 binding sites identified, .80% overlapped with H3K4me2 histone marks but not with transcription start sites, indicative of enhancer elements 5 (Fig. 1a, b , Supplementary Table 1 ).
To identify Pit1 interacting factors, we immunoprecipitated haemagglutinin (HA)-tagged Pit1 from 293T cells, and using mass spectrometry, identified matrin-3 and heterogeneous nuclear ribonucleoprotein U (HNRNPU) as two highly abundant proteins interacting with Pit1 ( Fig. 1c, Supplementary Tables 2, 3 ). The interactions were confirmed by co-immunoprecipitation/western blot experiments in 293T cells (Extended Data Fig. 1c ) and with endogenous proteins in GC cells (Fig. 1d, Extended Data Fig. 1d ). Both matrin-3 and HNRNPU have been previously found in a salt extraction-resistant nuclear fraction, as part of an internal fibrogranular network 6, 12, 13 which we term the nuclear matrin-3-rich network (Extended Data Fig. 1e ). These proteins bind DNA at sites known as matrix/scaffold attachment regions 13 .
ChIP-seq using a specific anti-matrin-3 antibody revealed that .50% of matrin-3 binding sites co-localized with H3K4me2 peaks (Extended Data Fig. 1f ), showing significant enrichment (,16-fold, P value , 10 2100 ) over the ,3% predicted random co-localization with H3K4me2 peaks, covering ,5% of the rat genome. Of these matrin-3/H3K4me2 sites, ,80% were elements distal to transcription start sites ( Fig. 1e ). This finding provides an initial demonstration of matrin-3 association with DNA regulatory sequences in the genome. We noticed that Pit1associated H3K4me2, H3K4me1 and H3K27Ac-marked enhancers, colocalized with matrin-3 ( Fig. 1f , g, Extended Data Fig. 1g ), and confirmed matrin-3 antibody specificity by knockdown of endogenous matrin-3 protein (Extended Data Fig. 1h , i). To investigate whether regulatory elements bound by Pit1 occupy the same nuclear compartment as matrin-3, we performed immuno-fluorescence in situ (FISH) experiments with DNA-FISH probes specific to the growth hormone (GH) locus and antimatrin-3 antibodies, finding that .65% of the FISH signals co-localized with matrin-3 ( Fig. 1h , Extended Data Fig. 1j ).
Because the pituitary specific homeodomain protein, Prop1, interacts with b-catenin to activate target gene expression 14 , we investigated b-catenin interacting partners in differentiated pituitary cells by expressing b-catenin fused to the biotin ligase recognition peptide (BLRP), along with biotinylating enzyme BirA, in GC cells. Biotinylated b-catenin was present in both the cytoplasmic and the nuclear compartments ( Fig. 2a , Extended Data Fig. 2a ). Streptavidin pull-down, followed by mass spectrometry, revealed that whereas cytoplasmic b-catenininteracting factors included a-catenin, as previously described 15 , Pit1 peptides predominated in the nuclear b-catenin fraction ( Fig. 2a , Supplementary Tables 4-7) . This putative Pit1-b-catenin interaction was confirmed between endogenous proteins by co-immunoprecipitation/ western blot experiments using nuclear extracts from GC pituitary cells ( Fig. 2b ). Using glutathione-S-transferase (GST) pull-down assays, armadillo repeats 8-12 of b-catenin proved sufficient to mediate this interaction, exactly within a region that has been previously described to interact with Prop1 (ref. 14) as well as Lef/Tcf 16 (Fig. 2c , Extended Data Fig. 2b ).
We then examined whether b-catenin plays a role in regulating expression of Pit1 target genes, such as GH. Effective knockdown of bcatenin in GC cells (Extended Data Fig. 2c ) markedly decreased the level of nascent GH transcripts ( Fig. 2d ), analogous to what was observed when Pit1 was knocked down (Fig. 2d , Extended Data Fig. 2c ). b-catenin also forms a complex with Satb1 (ref. 17 ), a well-established genome organizer essential for multiple biological processes, including T-cell activation and cancer progression 8, 18, 19 . Reverse transcription coupled with quantitative PCR (RT-qPCR) analysis revealed that the upregulation of Satb1 expression in the mouse pituitary gland coincides with differentiation of Pit1 lineages during pituitary development (Extended Data Fig. 2d ), and immunohistochemical analysis confirmed that SATB1 protein is expressed in somatotropes and other cells of the mouse pituitary gland (Extended Data Fig. 2e ). Co-immunoprecipitation of Pit1 from GC cells revealed an interaction with Satb1 ( Fig. 2b) which was reproduced by co-immunoprecipitation of HA-tagged Pit1 in 293T cells (Extended Data Fig. 2f ). Indeed, conditional knockout of Satb1 in the mouse anterior pituitary significantly decreased expression of GH (Extended Data Fig. 2g ). We therefore investigated whether interaction between Pit1 and Satb1 was dependent on b-catenin, and vice-versa. Exogenously expressed, HA-tagged Pit1 protein was pulled down after knocking down either b-catenin or Satb1 in 293T cells. In the absence of b-catenin, the 
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interaction between Pit1 with Satb1 was diminished, indicating a role for b-catenin in mediating Pit1-Satb1 interaction. Reciprocally, the interaction of Pit1 with b-catenin was partially abolished by Satb1 knockdown ( Fig. 2e ). Pit1 has been shown previously to co-fractionate with the insoluble, matrin-3 rich, nuclear fraction in in-vitro biochemical studies 20 . We therefore used lithium 3,5-diidosalicylate (LIS), a chaotropic reagent that extracts a majority of nuclear proteins but preserves the nuclear matrin-3-rich network 21 , to investigate Pit1 subnuclear locations (Extended Data Fig. 2h ). We observed that, in somatotropes, Pit1 indeed co-fractionated with matrin-3 and Satb1 in the LIS resistant insoluble fraction, while b-catenin was partitioned between the insoluble and soluble fractions (Extended Data Fig. 2i ). When both b-catenin and Satb1 proteins were simultaneously depleted (Extended Data Fig. 2j ), the presence of Pit1 in the LIS resistant insoluble fraction was significantly reduced (Fig. 2f ). In the double knockdown, total Pit1 protein levels were unchanged and Pit1 protein remained localized to the nucleus (Extended Data Fig. 2k ); however, it was now detectable in the looped-out DNA fraction obtained after DNAase I digestion of nuclear halos (Extended Data Fig. 2l ). Together, these data indicate that localization of Pit1 protein to the insoluble fraction is dependent on interaction with b-catenin and Satb1. Additionally, when endogenous Pit1 protein was pulled down before and after knocking down both b-catenin and Satb1 in GC cells, the absence of these proteins highly affected interaction between Pit1 and matrin-3 ( Fig. 2g ).
To further investigate whether association of Pit1-bound enhancers with the matrin-3 fraction is indeed dependent on b-catenin and SATB1, we performed immuno-FISH experiments in GC cells with anti-matrin-3 antibodies and DNA-FISH probes specific to the growth hormone (GH) locus. In GH-expressing GC cells, ,65% of the FISH signals colocalized with matrin-3. When both b-catenin and Satb1 were depleted, only ,35% of FISH signals loci co-localized with matrin-3, similar to the overlap of a GH locus in a Pit-1 positive, GH-non-expressing cell line (MMQ) (Fig. 2h , Extended Data Fig. 2m ). We thus conclude that association of Pit1 enhancers with the nuclear matrin-3-rich network/ structure observed by immuno-FISH ( Fig. 1h, Fig. 2h ) and biochemical extractions ( Fig. 2f , Extended Data Fig. 2h ) is dependent on intact interactions of Pit1 with both b-catenin and Satb1.
Global run-on (GRO-seq) analysis using GC cells before and after simultaneous knockdown of both b-catenin and Satb1 revealed that in total, 1,350 coding gene nascent transcripts were downregulated and 916 genes were upregulated under these double-knockdown conditions (Extended Data Fig. 3a ). Out of the 1,350 genes positively regulated by both b-catenin and SATB1 (Supplementary Table 8 ), 991 had Pit1-bound enhancer elements within 200 kbp of their start sites (Extended Data Fig. 3a ), and all 991 were significantly downregulated ( Fig. 3a) . Consistent with their functional importance 22 the expression of the eRNAs associated with these 991 Pit1-bound enhancers was significantly affected in the simultaneous knockdown of b-catenin and Satb1 (Fig. 3b ). ChIP-seq analysis revealed that Satb1 and b-catenin proteins were located at the centre of Pit1-positive enhancers (Extended Data Fig. 3b-d) , strongly supporting the co-binding model of these three proteins. Based on this analysis, we selected several highly downregulated genes that contain Pit1 enhancers (Extended Data Fig. 3c ) and observed that knockdown of either of the two proteins significantly diminished target gene expression (Extended Data Fig. 3g ). Additionally, knockdown of either Pit1 or b-catenin affected Satb1 association with enhancer elements, as assessed by ChIP-qPCR ( Fig. 3c, Extended Data Fig. 3e ). Association of matrin-3 with Pit1-dependent enhancers was significantly reduced when either b-catenin or SATB1 were downregulated (Extended Data Fig. 3h ). Finally, we confirmed that lack of Pit1 protein inhibited association of selected Pit1-dependent enhancers with matrin-3 ( Fig. 3d , Extended Data Fig. 3f ). Together, these data suggest that functional interaction between Pit1-dependent regulatory elements and matrin-3 requires association of the DNA-bound Pit1 with b-catenin and SATB1. Consistent with this suggestion, lack of matrin-3 had a negative effect on the expression of target genes (Extended Data Fig. 3i ).
Naturally occurring mutations in Pit1 underlie number of combined pituitary hormone deficiency (CPHD) cases in humans, with the R271 residue being the most frequently mutated 9 . Amino acid 271 maps to the last turn of helix 3 in the homeodomain and is located outside the DNA-binding surface. Although the R271W mutation in Pit1 confers dominant-negative properties (Extended Data Fig. 4a) 9 , it does not affect protein stability or binding to its cognate DNA sites (Extended Data Fig. 4b-d) 9 . We therefore investigated whether the R271W mutation affects the composition of the Pit1 complex. Co-immunoprecipitation of recombinant HA-tagged Pit1 proteins followed by western blot analysis revealed that the R271W mutation disrupted the ability of Pit1 to interact with matrin-3 and HNRNPU, apparently owing to its inability to bind b-catenin and Satb1 (Fig. 4a) . Additionally, biochemical fractionation indicated that the R271W mutant is largely lost from the insoluble fraction (Fig. 4b) , although both wild-type and R271W proteins were expressed at similar levels and found entirely localized to the nucleus (Extended Data Fig. 4e ). Instead, R271W was detected in the 
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'looped-out DNA' fraction ( Fig. 4b ), suggesting that it had lost its ability to interact with the LIS-resistant fraction. Together, these data indicated that a key function of homeodomain transcription factors such as Pit1 might be to join bound regulatory regions to the matrin-3-rich network, an association required to activate target gene transcription. Because the transcriptionally inactive R271W mutation interferes with this association, we experimentally tested this hypothesis by artificially tethering the R271W mutant to the matrin-3 network to try to restore target gene transcription. Several protein domains that are responsible for association with the matrin-3-rich 'matrix attachment regions' have been previously described and include the SAF/ SAP domain (for example, in HNRNPU 23 , SAF-B, PARP proteins 24 ); AT-hooks (HMG proteins 25 ); and the atypical homeodomain, SATB1 18 . We therefore grafted the SAF/SAP domain from rat HNRNPU (amino acids 4-45), onto HA-tagged wild-type and R271W Pit1 (Fig. 4c ). As predicted, R271W-SAF hybrid protein localized efficiently in the insoluble nuclear fraction (Extended Data Fig. 4f ). Hybrid wild-type (WT)-SAF and R271W-SAF proteins were expressed in GC cells treated with short interfering RNAs to deplete endogenous Pit1 (Extended Data Fig. 4g ). As expected, matrin-3 association with Pit1-dependent enhancers and expression of Pit1-dependent coding genes and eRNAs were lost upon Pit1 knockdown, but were restored in the presence of either wild-type or WT-SAF Pit1 (Fig. 4d, Extended Data Fig. 4i ). In contrast, neither the association of Pit1 enhancers with matrin-3 nor target gene and eRNA expression were rescued in R271W-expressing cells. However, the R271W-SAF hybrid rescued matrin-3 interaction and Pit1 transcriptional activation to levels close to those achieved by wild-type Pit1. These experiments indicate that specific subnuclear localization of Pit1 is a bona fide requirement for its full activity, and that this is the only functional defect in the R271W mutant Pit1 protein.
To investigate which step of enhancer activation is affected by R271W, we tested recruitment of p300, functional homologue of CREB binding protein (CBP), a known co-factor of Pit1 26 , finding that p300 association with tested enhancer elements was significantly reduced (Extended Data Fig. 4h ). Overexpression of R271W was not able to rescue this recruitment whereas hybrid R271W-SAF did restore p300 association with Pit1 bound enhancers (Extended Data Fig. 4h ). These data suggest that eRNA transcription and binding of critical co-activators, such as p300, require recruitment of Pit1 to the matrin-3-rich network.
To further substantiate these observations in intact pituitary, ex vivo rescue approach took advantage of the ''Snell'' mouse model that harbours a mutation (W261C) in Pit1 that renders it incapable of binding 
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to cognate DNA sites. Overexpressing HA-tagged Pit1-R271W-SAF hybrid, but not Pit1-R271W protein, rescued expression of endogenous GH as visualized by immunohistochemistry ( Fig. 4e ). On the basis of these data, we propose a model in which Pit1 association with the matrin-3-rich network is indispensable for its biological activity, as demonstrated by the lack of transcriptional activity of the naturally occurring mutant R271W Pit1 (Fig. 4f) .
Nuclear organization and genome three dimensional structure are postulated to have a prominent role in regulation of gene expression 28, 29 . Here, we have presented evidence that a homeodomain transcription factor regulates gene transcriptional programs through interaction with components of subnuclear structure (for example, matrin-3-rich structure). Other homeodomain proteins (for example, Lhx3, Prop1, Oct1), as well as different classes of transcription factors 30 , have been shown to associate with the high-salt extraction-resistant fraction, corresponding to the matrin-3-rich network. This suggests a model in which this interaction may be required for transcriptional activation of enhancers regulated by many homeodomain proteins, and perhaps several other types of DNA binding transcription factors.
Online Content Methods, along with any additional Extended Data display items and Source Data, are available in the online version of the paper; references unique to these sections appear only in the online paper.
METHODS
Antibodies. The antibodies used in this study are listed in Supplementary Table 9 . siRNA and expression vector electroporations. siRNA and overexpression experiments in GC cells and in P2 pituitary were performed using Neon system (Invitrogen). Conditions of 2 pulses of 1,150 V with 30 ms spacing were used. 2.5 mM siRNA and 30 mg of DNA were used per 3 3 10 6 cells. Knockdown was repeated after 48 h to obtain optimal depletion of the protein, verified by western blotting. Overexpression experiments were harvested after 48 h. siRNAs used in the study are listed in Supplementary Table 10 . SiRNA and overexpression experiments in 293T cells were performed using Lipofectamine 2000 (Invitrogen) using manufacturer's protocol. RT-qPCR. RNA was isolated using TRIzol (Invitrogen) and total RNA was reverse transcribed using SuperScript III Reverse Transcriptase (Invitrogen). Quantitative PCRs were performed mostly with SsoAdvanced SYBR Green Supermix (BIO-RAD). For normalization, DC t values were calculated relative to the levels of GAPDH transcripts. The experiments were repeated at least three times as a biological replicates, P values were obtained using a two-tailed Student's t-test; 6s.d.; *P , 0.05, **P , 0.01, ***P , 0.001; primers are listed in Supplementary Table 10 . ChIP-seq. ChIP was performed as previously described 1 . Briefly, for ChIP-seq, approximately 10 7 cells were cross-linked with 1% formaldehyde at room temperature for 10 min and neutralized with 0.125 M glycine. After sonication, 20-30 mg of soluble chromatin was incubated with 1-5 mg of antibody at 4 uC overnight. Immunoprecipitated complexes were collected using G-protein Dynabeads (Invitrogen). Subsequently, immuno-complexes were washed, and DNA was extracted and purified by QIAquick Spin columns (Qiagen). For ChIP-seq, the extracted DNA was ligated to specific adaptors followed by deep sequencing with the Illumina's HiSeq 2000 system according to the manufacturer's instructions. Usually, the first 48 bp for each sequence tag returned by the Illumina Pipeline was aligned to the rn4 assembly using BFAST or Bowtie2. Only uniquely mapped tags were selected for further analysis. The data was visualized by preparing custom tracks on the UCSC genome browser using HOMER (http://homer.salk.edu/homer). The total number of mapable reads was normalized to 10 7 for each experiment presented in this study. Identification of ChIP-seq peaks. The ChIP-seq peaks were identified by HOMER. Given different binding patterns of transcription factors and histones, parameters were optimized for the narrow tag distribution characteristic of transcription factors by searching for high read-enrichment regions within a 200-bp sliding window. Regions of maximal density exceeding a given threshold were called as peaks, and adjacent peaks were set to be .500 bp away to avoid redundant detection. The common artefacts from clonal amplification were circumvented by considering only one tag from each unique genomic position. The threshold was set at a false discovery rate (FDR) of 0.001 determined by peak finding using randomized tag positions in a genome with an effective size of 2 3 109 bp. For ChIP-seq of histone marks, seed regions were initially found using a peak size of 500 bp (FDR , 0.001) to identify enriched loci. Enriched regions separated by ,1 kb were merged and considered as blocks of variable lengths. All called peaks were then associated with genes by cross-referencing with the RefSeq TSS database. Peaks from individual experiments were considered overlapping if their peak centres were located within 200 bp (for some analyses the distance between them could extend to 1 kb). The peaks within 6 1 kb apart from the RefSeq gene TSS site were considered to be promoter bound. GRO-seq. GRO-seq experiments were performed as previously reported 31, 32 . Briefly, GC cells were swelled in swelling buffer (10 mM Tris-Cl pH 7.5, 2 mM MgCl 2 , 3 mM CaCl 2 ) for 5 min on ice and then lysed in lysis buffer (swelling buffer with 0.5% IGEPAL and 10% glycerol) before being finally re-suspended in 100 ml of freezing buffer (50 mM Tris-Cl pH 8.3, 40% glycerol, 5 mM MgCl 2 , 0.1 mM EDTA). For the run-on assay, re-suspended nuclei were mixed with an equal volume of reaction buffer (10 mM Tris-Cl pH 8.0, 5 mM MgCl 2 , 1 mM dithiothreitol (DTT), 300 mM KCl, 20 units of Superase-In, 1% sarkosyl, 500 mM ATP, GTP, Br-UTP and 2 mM CTP) and incubated for 5 min at 30 uC. The nuclear-run-on RNA (NRO-RNA) was then extracted with TRIzol LS reagent (Invitrogen) following the manufacturer's instructions. After base hydrolysis on ice for 40 min and followed by treatment with DNase I and Antarctic phosphatase, the Br-UTP-labelled NRO-RNA was purified by anti-BrdU agarose beads (Santa Cruz Biotech) in binding buffer (0.5 3 SSPE, 1 mM EDTA, 0.05% Tween) for 3 h at 4 uC while rotating. Then T4 PNK (NEB) was used to repair the end of NRO-RNA. Subsequently, complementary DNA synthesis was performed as reported with few modifications. The RNA fragments were subjected to the poly-A-tailing reaction by poly-A polymerase (NEB) for 30 min at 37 uC. Reverse transcription was then performed using superscript III (Invitrogen) with oNTI223 primer (for sequence see Supplementary Table 10 ). The cDNA products were separated on a 10% polyacrylamide TBE-urea gel with the right product (,100-500 bp) being excised and recovered by gel extraction. After that, the first-strand cDNA was circularized by CircLigase (Epicentre) and re-linearized by Ape1 (NEB). Re-linearized single-strand cDNA was separated by TBE gel and the products of the desired size were excised (,120-320 bp) for gel extraction. Finally, the cDNA template was amplified by PCR using the Phusion High-Fidelity enzyme (NEB) with primers oNTI200 and oNTI201 for deep sequencing (primers listed in Supplementary Table 10 ). GST-affinity purification and protein interaction studies. GST-b-catenin fusion vectors for protein interactions (gift from C. Neuveut) were expressed in Escherichia coli and purified from homogenized lysates with glutathione-agarose beads at 25 uC for 1 h. For interaction studies, similar amounts of immobilized GST-fusion proteins were then mixed with equal amounts of 293T cell lysates containing overexpressed, HA-tagged Pit1 protein and washed 43 with 13PBS with 10 mM DTT and protease inhibitors. Interacting proteins were eluted with 20 mM L-glutathione pH 8.0 and visualized by western blotting. Immunoprecipitation. Cells were collected with cold PBS and lysed with Dignam buffer C (20 mM HEPES pH 7.9, 25% glycerol, 420 mM NaCl, 1.5 mM MgCl2, 0.2 mM EDTA, 0.5 mM DTT, protease inhibitors). The lysate was diluted with dilution buffer (20 mM HEPES pH 7.9, 1.5 mM MgCl 2 , 0.2 mM EDTA, 0.5 mM DTT, protease inhibitors) to the final 150 mM NaCl concentration. 2-5 mg of antibodies were added into the diluted cell lysate and incubated overnight at 4 uC. The next day, the protein complexes were collected by magnetic Dynabeads G for 2 h at 4 uC with rotation. The beads-antibody-protein complexes were then washed four times with wash buffer (PBS, 0.03% Triton X-100) and boiled for western blot analysis. For cytoplasmic/nuclear analysis and immunoprecipitation followed by liquid chromatography and tandem mass spectrometry (LC-MS-MS) nuclei were isolated (using standard Dignam protocol) before lysis. Sample preparation for LC-MS-MS. Protein samples were diluted in TNE (50 mM Tris pH 8.0, 100 mM NaCl, 1 mM EDTA) buffer. RapiGest SF reagent (Waters Corp.) was added to the mix to a final concentration of 0.1% and samples were boiled for 5 min. TCEP (Tris (2-carboxyethyl) phosphine) was added to 1 mM (final concentration) and the samples were incubated at 37 uC for 30 min. Subsequently, the samples were carboxymethylated with 0.5 mg ml 21 of iodoacetamide for 30 min at 37 uC followed by neutralization with 2 mM TCEP (final concentration). Proteins samples prepared as above were digested with trypsin (trypsin:protein ratio 1:50) overnight at 37 uC. RapiGest was degraded and removed by treating the samples with 250 mM HCl at 37 uC for 1 h followed by centrifugation at 14,000 r.p.m. for 30 min at 4 uC. The soluble fraction was then added to a new tube and the peptides were extracted and desalted using C18 desalting columns (Thermo Scientific). LC-MS-MS analysis. Trypsin-digested peptides were analysed by ultrahigh pressure liquid chromatography (UPLC) coupled with tandem mass spectroscopy (LC-MS/MS) using nano-spray ionization. The nano-spray ionization experiments were performed using a TripleT of 5600 hybrid mass spectrometer (ABSCIEX) interfaced with nano-scale reversed-phase UPLC (Waters corporation nano ACQUITY) using a 20 cm-75 micron ID glass capillary packed with 2.5-mm C18 (130) CSHTM beads (Waters corporation). Peptides were eluted from the C18 column into the mass spectrometer using a linear gradient (5-80%) of ACN (acetonitrile) at a flow rate of 250 ml min 21 for 1 h. The buffers used to create the ACN gradient were: buffer A (98% H 2 O, 2% ACN, 0.1% formic acid, and 0.005% trifluoroacetic acid (TFA)) and buffer B (100% ACN, 0.1% formic acid, and 0.005% TFA). MS/MS data were acquired in a data-dependent manner in which the MS1 data was acquired for 250 ms at m/z of 400 to 1,250 Da and the MS/MS data was acquired from m/z of 50 to 2,000 Da. The independent data acquisition (IDA) parameters were as follows; MS1-TOF acquisition time of 250 ms, followed by 50 MS2 events of 48 ms acquisition time for each event. The threshold to trigger MS2 event was set to 150 counts when the ion had the charge state 12, 13 and 14. The ion exclusion time was set to 4 s. Finally, the collected data were analysed using Protein Pilot 4.5 (ABSCIEX) for peptide identifications. Three-dimensional-immuno-FISH. Cells were grown on poly-lysine coated cover slips. For immuno-FISH cells were fixed with 4% formaldehyde and permeabilized with 0.5% Triton X-100 followed by glycerol wash and freezing in liquid nitrogen. Cells were then treated with 0.1 M HCl and with pepsin. Cells were then washed, blocked in 4% BSA and incubated with the primary anti-matrin-3 antibody (ab70336). The cover slips were incubated with a biotinylated secondary antibody (Vector Labs BA-1000) followed by fluorescent streptavidin and post-fixed cells at 4% paraformaldehyde. The cover slips were then immersed in 50%formamide/2XSSC. The DNA on the slides was denatured together with fluorescent probes for 10 min at 76 uC. The probes were prepared from BACS (purchased from Children's Hospital Oakland Research Institute) using a nick translation kit according to the manufacturer's instructions (Roche). Hybridization took place at 37 uC for at least 2 days in a humid chamber. After hybridization cover slips were washed in 50% formamide/23SSC and in 0.53SSC. Afterwards the cover slips were incubated with the appropriate fluorescent secondary antibodies, washed and mounted on slides with ProLong gold containing DAPI. The images were taken using an Olympus FV1000 confocal microscope.
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